Gene-Edited cell therapy for lupus trial pulled before it started
NCT ID NCT06752876
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study aimed to test a single infusion of CB-010, a CRISPR-edited CAR-T cell therapy made from donor cells, in people with severe lupus that did not respond to standard treatments. The trial was withdrawn before enrolling any participants, so no results are available. The approach was designed to target and destroy faulty immune cells that drive lupus, but its safety and effectiveness remain untested.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CB-010 (a CRISPR-edited CAR-T cell therapy made from donor cells)
- What this could lead to
- If it works, this could point toward a new treatment option for people with severe lupus that hasn't responded to other therapies.
- What could go wrong
- This trial was withdrawn before enrolling any participants, so no data is available. CAR-T therapies carry risks like cytokine release syndrome and infections, and long-term safety is unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal kidney damage in lupus — no biopsy needed?
- Can a Three-Drug combo quiet lupus kidney flares?
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can a new biologic tame lupus flares?
- Could a single injection tame lupus and Sjögren's?
- Can a single infusion tame tough lupus?